97 related articles for article (PubMed ID: 25003567)
1. TNBC vs non-TNBC: A retrospective review of differences in mean age, family history, smoking history, and stage at diagnosis.
Tariq K; Farhangi A; Rana F
Clin Adv Hematol Oncol; 2014 Jun; 12(6):377-81. PubMed ID: 25003567
[TBL] [Abstract][Full Text] [Related]
2. TNBC vs. Non-TNBC: A Five-Year Retrospective Review of Differences in Mean Age, Family History, Smoking History and Stage at Diagnosis at an Inner City University Program.
Tariq K; Rana F
World J Oncol; 2013 Dec; 4(6):241-247. PubMed ID: 29147364
[TBL] [Abstract][Full Text] [Related]
3. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer: An institutional analysis.
Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK
Indian J Cancer; 2014; 51(2):163-6. PubMed ID: 25104201
[TBL] [Abstract][Full Text] [Related]
5. Age-related frequency of triple negative breast cancer in women.
Sajid MT; Ahmed M; Azhar M; Mustafa QU; Shukr I; Ahmed M; Kamal Z
J Coll Physicians Surg Pak; 2014 Jun; 24(6):400-3. PubMed ID: 24953912
[TBL] [Abstract][Full Text] [Related]
6. Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
Tung N; Gaughan E; Hacker MR; Lee LJ; Alexander B; Poles E; Schnitt SJ; Garber JE
Breast Cancer Res Treat; 2014 Jul; 146(1):175-82. PubMed ID: 24839033
[TBL] [Abstract][Full Text] [Related]
7. A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients.
Seong MW; Kim KH; Chung IY; Kang E; Lee JW; Park SK; Lee MH; Lee JE; Noh DY; Son BH; Park HL; Cho SI; Park SS; ; Kim SW
Breast Cancer Res Treat; 2014 Jul; 146(1):63-9. PubMed ID: 24894343
[TBL] [Abstract][Full Text] [Related]
8. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.
Baser O; Wei W; Henk HJ; Teitelbaum A; Xie L
Curr Med Res Opin; 2012 Mar; 28(3):419-28. PubMed ID: 22364568
[TBL] [Abstract][Full Text] [Related]
9. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
[TBL] [Abstract][Full Text] [Related]
10. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.
Lara-Medina F; Pérez-Sánchez V; Saavedra-Pérez D; Blake-Cerda M; Arce C; Motola-Kuba D; Villarreal-Garza C; González-Angulo AM; Bargalló E; Aguilar JL; Mohar A; Arrieta Ó
Cancer; 2011 Aug; 117(16):3658-69. PubMed ID: 21387260
[TBL] [Abstract][Full Text] [Related]
11. Platinum-based chemotherapy in triple-negative advanced breast cancer.
Villarreal-Garza C; Khalaf D; Bouganim N; Clemons M; Peña-Curiel O; Baez-Revueltas B; Kiss A; Kassam F; Enright K; Verma S; Pritchard K; Myers J; Dent R
Breast Cancer Res Treat; 2014 Aug; 146(3):567-72. PubMed ID: 25001611
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC.
Biswas T; Efird JT; Prasad S; James SE; Walker PR; Zagar TM
Clin Breast Cancer; 2016 Jun; 16(3):212-6. PubMed ID: 26988771
[TBL] [Abstract][Full Text] [Related]
13. Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities.
Parise CA; Caggiano V
Breast Cancer Res Treat; 2017 May; 163(1):151-158. PubMed ID: 28213780
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative breast cancer is not associated with increased likelihood of nodal metastases.
Gangi A; Mirocha J; Leong T; Giuliano AE
Ann Surg Oncol; 2014 Dec; 21(13):4098-103. PubMed ID: 25155393
[TBL] [Abstract][Full Text] [Related]
15. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
[TBL] [Abstract][Full Text] [Related]
16. Racial and ethnic disparities in the diagnosis of breast cancer: changes in presenting stage in minority populations in Florida during 1981-2009.
Dosch AR; Koru-Sengul T; Miao F; Tannenbaum SL; Byrne MM; Wright JL
Breast Cancer Res Treat; 2014 Nov; 148(2):379-87. PubMed ID: 25301087
[TBL] [Abstract][Full Text] [Related]
17. Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study.
Rapiti E; Pinaud K; Chappuis PO; Viassolo V; Ayme A; Neyroud-Caspar I; Usel M; Bouchardy C
Cancer Med; 2017 Mar; 6(3):526-536. PubMed ID: 28211614
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer survival in Iranian patients.
Aghili M; Lashkari M; Farrokhpey AH; Izadi S
Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
[TBL] [Abstract][Full Text] [Related]
19. An institutional analysis of clinicopathological features of triple negative breast cancer.
Sharma D; Singh G
Indian J Cancer; 2016; 53(4):566-568. PubMed ID: 28485352
[TBL] [Abstract][Full Text] [Related]
20. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
